Selected article for: "growth factor and lung fibrosis"
Author: Qiu, Yingshan; Lam, Jenny K. W.; Leung, Susan W. S.; Liang, Wanling
Title: Delivery of RNAi Therapeutics to the Airways—From Bench to Bedside
  • Document date: 2016_9_20
    • ID: 04pp3lv0_73
    Snippet: RNAi has been exploited to suppress the production of key molecules involved in the fibrotic process, such as TGF-β [92, 224] , amphiregulin (AR) and connective transforming growth factor (CTGF) [8, 225] (Table 5) . Clinical trials examining the effect of neutralized antibodies to block the activity of TGF-β are currently ongoing [14] . Since lung epithelial cells are the key cell types in the pathogenesis of pulmonary fibrosis, local administr.....
    Document: RNAi has been exploited to suppress the production of key molecules involved in the fibrotic process, such as TGF-β [92, 224] , amphiregulin (AR) and connective transforming growth factor (CTGF) [8, 225] (Table 5) . Clinical trials examining the effect of neutralized antibodies to block the activity of TGF-β are currently ongoing [14] . Since lung epithelial cells are the key cell types in the pathogenesis of pulmonary fibrosis, local administration of RNAi targeting TGF-β to the lungs can ensure high local concentration of RNAi molecules to produce therapeutic effects. Intratracheal delivery of siRNA targeting TGF-β1 could effectively inhibit pulmonary fibrosis, improved lung function, and prolonged survival in human TGF-β1 transgenic mice [224] . In another in vivo study, intranasal delivery of miRNA-326 mimic, which was designed to suppresses the expression of TGF-β and other profibrotic genes, significantly reduced TGF-β1 expression level and further alleviated the fibrotic feature in the bleomycin-induced pulmonary fibrosis [92] . The results suggest the potential of targeting TGF-β or its signaling pathway using RNAi technology for the management of lung fibrosis. Notes: AR, amphiregulin; CCL2, chemokine (C-C motif) ligand 2/monocyte chemoattractant protein-1; CTGF, connective tissue growth factor; PDGF, platelet-derived growth factor; PDMAEMA, poly(dimethylamino)ethylmethacrylate; PMAPEG: poly(methylether-methacrylate-ethyleneglycol); SAMiRNA, self-assembled micelle interfering RNA; TGF-β, transforming growth factor β.

    Search related documents:
    Co phrase search for related documents
    • lung epithelial cell and pulmonary fibrosis pathogenesis: 1
    • lung epithelial cell and signal pathway: 1
    • lung epithelial cell and therapeutic effect: 1
    • lung epithelial cell and transgenic mouse: 1, 2
    • lung epithelial cell and vivo study: 1, 2, 3
    • lung fibrosis and therapeutic effect: 1, 2, 3, 4, 5, 6, 7
    • lung fibrosis and tissue growth factor: 1, 2
    • lung fibrosis and transgenic mouse: 1
    • lung fibrosis and vivo study: 1, 2, 3, 4, 5, 6, 7
    • lung function and prolong survival: 1, 2
    • lung function and pulmonary fibrosis: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
    • lung function and pulmonary fibrosis inhibit: 1, 2
    • lung function and pulmonary fibrosis pathogenesis: 1, 2
    • lung function and RNAi technology: 1
    • lung function and signal pathway: 1, 2, 3, 4
    • lung function and TGF β target: 1
    • lung function and therapeutic effect: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • lung function and tissue growth factor: 1
    • lung function and vivo study: 1, 2, 3